Austin, TX and Lake Zurich, IL, May 16, 2023 (GLOBE NEWSWIRE) — QSAM Biosciences, Inc. (OTCQB: QSAM), a clinical stage biotechnology company developing next-generation therapeutic radiopharmaceuticals, and RLS (USA) Inc., the third-largest nuclear medicine pharmacy network in the U.S., announced today a commercial supply and clinical dose preparation agreement for…Read More
QSAM Biosciences and RLS Announce Clinical and Commercial Supply Agreement for Promising ClinicalStage Metastatic and Primary Bone Cancer Treatment CycloSam
